ライフサイエンスコーパス: transplantation outcome

1 antibody-mediated-rejection, and unfavorable transplantation outcome.

2 on of SCID babies from infection and improve transplantation outcome.

3 orrelated and were significant predictors of transplantation outcome.

4 can potentially have a significant impact on transplantation outcome.

5 tential impact for immune responsiveness and transplantation outcome.

6 ogenic compounds could further improve islet transplantation outcome.

7 to see whether IFN pretreatment compromised transplantation outcome.

8 justment of the dialysis method can optimize transplantation outcome.

9 d the effect of a BMI >25 on long-term renal transplantation outcome.

10 re reduced or absent in patients with a poor transplantation outcome.

11 of the intestinal environment may influence transplantation outcomes.

12 uld monitor islet mass might help to improve transplantation outcomes.

13 ed transplantation to achieve desirable post-transplantation outcomes.

14 nce the occurrence of autoimmune disease and transplantation outcomes.

15 ht be crucial for improving long-term kidney transplantation outcomes.

16 ens new therapeutic options to improve liver transplantation outcomes.

17 HCT, we conducted an international survey of transplantation outcomes.

18 ntify individuals at risk for adverse kidney transplantation outcomes.

19 tic intervention and improvement of clinical transplantation outcomes.

20 y to develop risk-score categories for major transplantation outcomes.

21 egulation of immune responses that determine transplantation outcomes.

22 ies will be of assistance in improving islet transplantation outcomes.

23 for improving HSPC mobilization and thereby transplantation outcomes.

24 may be a useful strategy in improving islet transplantation outcomes.

25 f 2 mg/kg per day) does not compromise major transplantation outcomes.

26 s unclear what impact G-CSF has on long-term transplantation outcomes.

27 orative research initiatives in the field of transplantation outcomes.

28 Differences in kidney transplantation outcomes across GN subtypes have rarely

29 Postkidney transplantation outcomes among patients with Fabry disea

30 s and the effect of age on waitlist and post-transplantation outcomes and on transplant-related survi

31 This study sought to investigate post-transplantation outcomes as a function of race and panel

32 We review the pediatric stem cell transplantation outcomes as well as the pediatric experi

33 Using Cox regression analysis, we compared transplantation outcomes between groups.

34 the loss of these BH3-only proteins improves transplantation outcome, but recipients might be exposed

35 linic as induction therapy aiming to improve transplantation outcomes by reducing the need for long-t

36 Moreover, transplantation outcome can be improved by administering

37 influence graft-versus-host disease or other transplantation outcomes can provide additional clinical

38 antation were higher in patients with a good transplantation outcome compared with those patients who

39 We aimed to see if SPK transplantation outcomes differed between recipients fro

40 Donor KIR genotype influenced transplantation outcome for AML but not ALL.

41 hat iron overload plays an important role in transplantation outcome for patients with acute leukemia

42 Liver transplantation outcomes for HCC in these patients, howe

43 S data show no net advantage in the ultimate transplantation outcome, graft survival.

44 s I or II antigens of a donor panel on heart transplantation outcome has not been extensively studied

45 The importance of HLA matching for renal transplantation outcomes has been appreciated for severa

46 ignificance of this drug-drug interaction on transplantation outcomes has not been determined.

47 The influence of DSA-SPA on repeat renal transplantation outcomes has not been previously studied

48 The influence of DSA-SPA on repeat renal transplantation outcomes has not been previously studied

49 Genetic association studies of transplantation outcomes have been hampered by small sam

50 additional islet-helper cells would improve transplantation outcome in diabetic mice.

51 nhibitory KIR can be a prognostic factor for transplantation outcome in HLA-identical sibling transpl

52 _INS mRNA and SI_16h insulin predicted islet transplantation outcome in nonobese diabetic (NOD) scid

53 To identify useful prognostic indicators of transplantation outcome in postimatinib therapeutic inte

54 cant contribution of donor-activating KIR to transplantation outcome in these patients.

55 an leukocyte antigen mismatch ("vector") and transplantation outcomes in 1202 recipients of single CB

56 immunity-related GTPase family, M [IRGM]) on transplantation outcomes in 390 US patients and their ma

57 H-2(d)) to assess alloimmunization and islet transplantation outcomes in Akita recipients.

58 The purpose of this study was to compare transplantation outcomes in patients with hematologic ma

59 f the lung allocation score on wait-list and transplantation outcomes in patients with idiopathic pul

60 ring several strategies to improve alloislet transplantation outcomes in the future.

61 The best transplantation outcomes in Wiskott-Aldrich syndrome are

62 evaluated the association of mutations with transplantation outcomes, including overall survival, re

63 rate of infection and significantly improved transplantation outcome irrespective of donor choice, co

64 onor cells per kilogram recipient weight) on transplantation outcome is controversial and may differ

65 Because of the high cost, interest in transplantation outcomes is particularly intense.

66 h other and which have the greater impact on transplantation outcomes is, however, not clear.

67 The extent to which transplantation outcome may be improved with donor match

68 Factors associated with a good transplantation outcome need to be identified in order t

69 We report transplantation outcomes of 258 children with Hurler syn

70 Using similar models, waitlist and transplantation outcomes of patients with diabetes melli

71 cts of room-air oxygenation on pre- and post-transplantation outcomes of patients with HPS.

72 composite allograft (VCA) procurement on the transplantation outcomes of the concomitantly recovered

73 ratified Cox proportional hazards model, the transplantation outcomes of the SLE patients were compar

74 relating graft characteristics with clinical transplantation outcomes, on appropriate typing strategi

75 oes not appear to be associated with adverse transplantation outcomes over the first 3 years; however

76 xic therapy with double autologous stem cell transplantation, outcome remains poor for children with

77 strong gliotic response, and otherwise poor transplantation outcome (Rho(-/-)), leading to an eightf

78 ibrogenic phenotypes (M2 cells); they affect transplantation outcomes via diverse mechanisms.

79 he association of donor characteristics with transplantation outcomes was examined using either logis

80 To identify factors influencing transplantation outcome, we studied 452 recipients of HL

81 To identify predictive factors for transplantation outcome, we studied 519 patients with MD

82 The effects of 9 individual variables on transplantation outcomes were also examined, and the sta

83 Transplantation outcomes were compared between 1,052 URD

84 Thus, transplantation outcomes were compared in the prospectiv

85 Transplantation outcomes were not affected by the prepar

86 al transplant patients with SLE had inferior transplantation outcomes, with more than twice the risk

87 r cells during engraftment but also improves transplantation outcome without signs of adverse patholo